Capricor Therapeutics CAPR Stock Issuance Proceeds
Stock Issuance Proceeds at other companies
Other financials
Where this comes from
Reported directly by Capricor Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:ProceedsFromStockOptionsExercised.
The official record: Capricor Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Capricor Therapeutics's stock issuance proceeds.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Capricor Therapeutics's stock issuance proceeds?
- Capricor Therapeutics (CAPR) reported stock issuance proceeds of $1.47M in Q1 2026.
- How has Capricor Therapeutics's stock issuance proceeds changed year-over-year?
- Capricor Therapeutics's stock issuance proceeds increased by 2820.6% year-over-year, from $50.35K to $1.47M.
- What is the long-term trend for Capricor Therapeutics's stock issuance proceeds?
- Over 4 years (2021 to 2025), Capricor Therapeutics's stock issuance proceeds has grown at a 85.1% compound annual growth rate (CAGR), from $20.18M to $237.03M.
- What does stock issuance proceeds mean?
- Cash received from issuing common stock — IPOs, secondary offerings, DRIP, employee stock purchase plans, and option exercises.